Improved glycaemia during the Covid-19 pandemic lockdown is sustained post-lockdown and during the “Eat Out to Help Out” Government Scheme, in adults with Type 1 diabetes in the United Kingdom

Parizad Avari1,*, Rebecca Unsworth1,*, Siân Rilstone1, Chukwuma Uduku1, Karen M. Logan2, Neil E. Hill1, Ian F. Godsland1, Monika Reddy1, Nick Oliver1

1 Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom, 2 Department of Paediatrics, St Mary’s Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom

* These authors contributed equally to this work.
* p.avari@imperial.ac.uk

Abstract

Aims
The majority of studies report that the Covid-19 pandemic lockdown did not have a detrimental effect on glycaemia. We sought to explore the impact of lockdown on glycaemia and whether this is sustained following easing of restrictions.

Methods
Retrospective, observational analysis in adults and children with type 1 diabetes attending a UK specialist centre, using real-time or intermittently scanned continuous glucose monitoring. Data from the following 28-day time periods were collected: (i) pre-lockdown; (ii) during lockdown; (iii) immediately after lockdown; and (iv) a month following relaxation of restrictions (coinciding with Government-subsidised restaurant food). Data were analysed for times in glycaemic ranges and are expressed as median (IQR).

Results
145 adults aged 35.5 (25.8–51.3) years with diabetes duration of 19.0 (7.0–29.0) years on multiple daily injections of insulin (60%) and continuous insulin infusion (40%) were included. In adults, % time in range (70-180mg/dL) increased during lockdown (60.2 (45.2–69.3)% compared to pre-lockdown (56.7 (43.5–65.3)%; p<0.001). This was maintained in the post-lockdown time periods. Similarly, % time above range (>180mg/dL) reduced in lockdown compared to pre-lockdown (p = 0.01), which was sustained thereafter. In children, no significant changes to glycaemia were observed during lockdown. In multivariable analysis, a greater increase in %TIR 3.9-10mmol/L (70-180mg/dL) during lockdown was associated with higher levels of deprivation (coefficient: 4.208, 95% CI 0.588 to 7.828; p = 0.02).
Conclusions
Glycaemia in adults improved during lockdown, with people from more deprived areas most likely to benefit. This effect was sustained after easing of restrictions, with government-subsidised restaurant eating having no adverse impact on glycaemia.

1.0 Introduction
The coronavirus disease (COVID-19) outbreak caused by the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was defined by the World Health Organisation as a global pandemic on 11th March 2020 [1]. The UK government imposed a strict lockdown to slow the transmission of SARS-CoV-2 on 23rd March 2020 [2]. Both type 1 and type 2 diabetes are associated with increased mortality in hospitalized patients with COVID-19 [3], with a higher number of deaths in people with type 1 and type 2 diabetes living in the most deprived neighbourhoods compared to those living in the least deprived areas [3]. Furthermore, among people with diabetes, factors such as hyperglycaemia and obesity are independently associated with COVID-19 mortality [4]. SARS-CoV-2 may adversely affect glucose metabolism both directly by causing beta cell death and indirectly by increasing insulin resistance [5].

Type 1 diabetes (T1D) self-management can be challenging, involving multiple daily injections of insulin (MDI) or continuous subcutaneous insulin infusion (CSII), guided by self-monitoring of glucose [6].

Previous studies have compared glycaemic measures before and during lockdown in people with T1D using different glucose monitoring and insulin delivery modalities with the majority finding that lockdown has not had a detrimental effect [7–13]. Few studies have investigated glycaemic metrics following the end of lockdown during the relaxation of restrictions. These studies demonstrated sustained improvements for up to a 2-week period but have not investigated further [14–17].

In the UK, following lockdown, one of the Government’s policy measures to support businesses reopening, was the “Eat Out to Help Out Scheme (EOHO)”. Throughout August 2020, the EOHO scheme supported the hospitality sector by providing consumers a discount of up to 50% off food and drink (non-alcoholic) consumed in participating outlets with a maximum discount of £10 per meal per person, valid all day Monday, Tuesday and Wednesday. These included restaurants and pubs, with >78,000 outlets participating and over 160 million meals subsidised [18].

We aimed to explore the impact of lockdown and during the relaxation of restrictions in a diverse group of adults and children with T1D living in London and to assess the factors impacting glycaemia during this unprecedented change to people’s lifestyles, including use of glucose monitoring technologies or CSII and pre-lockdown glycaemic control (HbA1c and time in acceptable glycaemia range). We also explored the influence of deprivation according to the English indices of deprivation [19].

2.0 Methods
2.1 Inclusion and exclusion criteria
This is a retrospective observational analysis of all adults and children with T1D using real-time continuous glucose monitoring (rtCGM; Dexcom G6 or Medtronic) or intermittently scanned continuous glucose monitoring (isCGM; Freestyle Libre), who were under regular
care at Imperial College Healthcare NHS Trust (ICHNT) in London, UK. The groups were defined by the responsible clinical service as paediatric (<18 years old) or adult (≥18 years old). ICHNT is a specialist diabetes referral centre for northwest London, providing services to a diverse urban population. In addition, anonymised data from participants using rtCGM as part of the free-living research study: 'Assessment of the Impact of Real-Time Continuous Glucose Monitoring on People Presenting With Severe Hypoglycaemia (AIR-CGM; NCT03748433)' [20] at Imperial College London, were included.

Only participants with at least 70% of continuous glucose data available for both 28 day periods pre- and during lockdown were included. The requirement for at least 70% of glycaemic data was based on consensus recommendations for reporting % times in range [21]. Participants who did not meet the above criteria, had type 2 diabetes or women who were pregnant were excluded from analysis. The sample in these analyses may be considered representative of a larger population, however only reflects individuals with T1D on rtCGM or isCGM, and not those self-monitoring blood glucose.

2.2 Methods

2.2.1 Data collection and computation of glycaemic outcomes. Continuous glucose data were collected over 28 days prior to lockdown (15th February 2020 00:00hrs to 13th March 2020 23:59hrs) and compared with data of the same duration during lockdown (24th March 2020 00:00hrs to 20th April 2020 23:59hrs), immediately after lockdown (4th July 2020 00:00hrs to 31st July 2020 23:59hrs); and a month following relaxation of restrictions (1st August 2020 00:00hrs to 28th August 2020 23:59hrs) coinciding with the EOHO Government scheme in the U.K.

The study was entirely observational (with no deviation from standard clinical care) and ethics approval was not required. All individuals granted specific permission to share their glucose data with the clinical teams, and for clinic staff to access this, when linking their devices and uploading their data to web-based online software (Dexcom Clarity, LibreView, and Tidepool). NHS Research Ethics Committee review was not required. Data for analysis were de-identified before they were analysed, with participants identified solely by study number.

Percentage (%) times in glycaemic range and measures of glycaemic variability (GV) were computed using EasyGV (v10.0) software [22]. Outcomes measures included % time in range (TIR) 3.9–10mmol/L (70 - 140mg/dL), % time above range >10mmol/L (>180mg/dL; TAR1) and >13.9mmol/L (>250mg/dL; TAR2), and % time below range (TBR) <3.9mmol/L (<70mg/dL; TBR1), <3.0mmol/L (<54mg/dL; TBR2), and <2.8mmol/L (<50mg/dL; TBR3). Evaluated GV measures include standard deviation (SD), coefficient of variation (CV), low blood glucose index (LBGI) and mean absolute glucose change per unit time (MAG). Estimated glucose management index (GMI) was calculated using the following formula [23]:

\[
GMI \text{ (mmol/mol)} = 12.71 + 4.70587 \times [\text{mean glucose (mmol/L)}].
\]

There were no available data on lifestyle or therapy changes for diet, exercise or insulin use. IsCGM scanning frequency during these timeframes has been included in the analysis.

Socioeconomic deprivation was assessed by the English Indices of Deprivation 2019 [19] using postcodes. Deprivation deciles are based on the Index of Multiple Deprivation 2019 (IMD 2019). Decile 1 represents the most deprived 10% of neighbourhoods in England, whilst decile 10 represents the least deprived 10%.

2.2.2 Statistical methods. Changes in glucose outcome measures were analysed between baseline (pre-lockdown), during lockdown and for the two months post lockdown. Data (% TIR) were tested for normality using the Shapiro–Wilk test (p<0.05). The adult and paediatric groups were also analysed separately. Differences between pre- and during lockdown glucose
outcomes measures were tested for significance using Wilcoxon matched-pairs signed-rank tests. Sub-analysis comparisons in the adult cohort, justified by relatively large numbers of observations and significant variation between time points, explored differences according to insulin delivery and mode of glucose monitoring.

Further analysis was performed in those participants who also had at least 70% of glucose data for the two periods after lockdown. The non-parametric repeated measures Friedman statistical test was used to detect differences in glycaemia across the four different time points. To determine where the significant differences lay between the four time points for the adult cohort, the Wilcoxon matched-pairs signed-rank tests were performed as pairwise analyses.

Multivariable linear regression analysis of variation in glycaemic outcome measures was performed using the covariates: age, gender, sensor modality, insulin delivery method, baseline %TIR, baseline HbA1c and deprivation. Deprivation deciles were re-categorised according to the tertiles: severely deprived, moderately deprived and least deprived, the equal numbers in each category then providing for equal category weightings in the regression model. This analysis derived from observational data acquired in an unprecedented situation. Accordingly, no information was available for a prior power calculation and a threshold of statistical significance of $p < 0.05$ was adopted as an aid to interpretation rather than as a decision-making criterion. Statistical analyses were performed using Stata version 13 (StataCorp, College Station, TX).

### 3.0 Results

#### 3.1 Baseline demographics

We identified 145 individuals with at least 70% data uploaded pre- and during lockdown (S1 Fig). For adults and paediatrics combined, the median (interquartile range) age was 35.5 (25.8–51.3) years with diabetes duration of 19.0 (7.0–29.0) years and HbA1c of 7.7 (7.2–8.6)% (61 (55–70) mmol/mol). 75 participants (52%) were male, 58 (40%) were CSII users and 48 (33%) used rtCGM; 20 (14%) used both rtCGM and CSII. For the adults using rtCGM, more than a quarter (28%) had impaired awareness of hypoglycaemia (GOLD score ≥ 4) and/or ≥ 1 episode of severe hypoglycaemia in the past 1 year. Baseline characteristics of the participants are summarized for adults and paediatrics in Table 1.

#### 3.2 Improved glycaemia during lockdown in adults

For adults during lockdown, %TIR increased from 56.7 (43.5–65.3)% to 60.2 (45.2–69.3)% (Table 2; $p < 0.001$). A similar change was observed for % time in euglycaemia 3.9–7.8mmol/L (70-140mg/dL; Table 2; $p = 0.001$). In the sub-analysis by insulin delivery (CSII vs MDI; S1 Table) and glucose sensing modality (rtCGM vs isCGM; S2 Table), significant improvements in %TIR were observed for all subgroups. The median change in %TIR difference between pre- and during lockdown was +2.1 (-1.1 to +5.6)% in the MDI group ($p = 0.004$); +3.1 (-3.3 to +7.2)% in the CSII group ($p = 0.05$); +3.3 (-2.9 to +5.6)% in the rtCGM group ($p = 0.04$) and +2.4 (-1.8 to +6.9)% in the isCGM group ($p = 0.005$). There were no significant differences for median change in %TIR between the subgroups based on insulin delivery (MDI vs CSII) nor glucose sensing modality (isCGM vs rtCGM).

For %TAR1 and %TAR2, significant reductions were observed during the lockdown period ($p = 0.01$ and $p = 0.007$ respectively; Table 2). In the sub-analyses, a significant reduction was seen in %TAR1 for rtCGM users (median change -5.0 (-8.0 to -1.2)%; $p = 0.01$); and in %TAR2 for isCGM users (median change -0.9 (-3.4 to +0.9)%; $p = 0.02$). There were no between-group differences for MDI vs CSII, nor isCGM vs rtCGM.
For hypoglycaemia %TBR1 and %TBR2, no significant difference was observed from baseline to lockdown (Table 2). In the MDI group, significant reductions in hypoglycaemia for %TBR1 and %TBR3 were observed (p = 0.02 and p = 0.04 respectively). Between group differences revealed significant reduction in %TBR1 in MDI participants compared to CSII (p = 0.005). Significantly reduced hypoglycaemia was also noted in the group using isCGM for all %TBR thresholds, with no significant change in hypoglycaemia in the rtCGM users. There were no between-group differences in hypoglycaemia for the isCGM and rtCGM groups.

Mean glucose values and measures of variability (SD, CV and MAG) significantly reduced during lockdown in adults, except LBGI (p < 0.05; Table 2). Although trends were similar across all cohorts, significance was reached predominantly in MDI and isCGM users.

For individuals using isCGM, there were no significant differences in the number of independent scans performed by each individual (pre-lockdown 11 (7–16) scans/day vs during lockdown 10.5 (7–15) scans/day; p = 0.18).

### 3.3 Glycaemic outcomes in paediatrics

In the paediatric analysis pre- and during lockdown %TIR was 45.4 (33.8–60.8)% and 50.8 (35.0–61.1)% respectively, % time in euglycaemia was 28.3 (20.1–36.1)% and 32.2 (21.4–41.0)% respectively, with no statistically significant differences (Table 2). The %TBR did not differ before and during lockdown (Table 2). The changes in glycaemic variability measures are summarised in Table 2, with no statistically significant differences, except for a reduction in MAG from 3.2 (2.8–3.4) pre-lockdown to 3.0 (2.5–3.3) during lockdown (p = 0.01).

Similar to adults, there were no significant differences in the number of independent scans performed in the paediatric cohort.

### 3.4 Independent influences on lockdown glycaemia

Multivariable linear regression analysis (Table 3) suggested greater social deprivation was associated with an increase in %TIR (coefficient: 4.208 [95% CI 0.588 to 7.828]; p = 0.02) with a negative association with change in %TAR1 (coefficient: -4.746 [95% CI -8.771 to -0.721]; p = 0.02).

There was a significant association between rtCGM use and an increase in %TBR1 during lockdown (coefficient 1.498, 95% CI 0.393 to 2.603; p = 0.008). This association was not
observed with %TBR2 (coefficient: 0.518, 95% CI -0.036 to 1.072; p = 0.10). Increased %CV was also associated with rtCGM use during lockdown (coefficient: 0.019, 95% CI 0.004 to 0.035; p = 0.01). Age, gender, baseline HbA1c, baseline %TIR and insulin delivery method did not influence the effect of lockdown on %TIR.

### 3.5 Effect of deprivation

The overall median (IQR) deprivation deciles across the cohort for adults and children were 4 (3–7) (Table 1). At baseline, there were no significant differences in HbA1c between the two groups (62 (55–73) mmol/mol in deciles ≤ 4 vs 59 (55–67) mmol/mol in deciles ≥ 5; p = 0.12).

Individuals in the lower 50% of the deprivation scores (deciles ≤ 4 vs deciles ≥ 5) had significantly greater change in %TIR during lockdown than those in the upper 50% (change %TIR +3.25 (-0.38 to 8.71) vs +1.79 (-3.61 to 4.73) respectively; p = 0.02). The boxplot (S2 Fig) illustrates the change in %TIR for adults and children categorised into tertiles of index of deprivation.
3.6 Post-lockdown analysis

Further analysis was performed in the adult cohort who had data uploaded in the two months following the lockdown (the period 1 month after lockdown coinciding with the EOHO government scheme) (Table 4); n = 97 (S1 Fig). Between during and post-lockdown periods, there were no significant differences in %TIR. Similarly, the significant reduction in %TAR1 observed in lockdown compared to pre-lockdown (p = 0.04), was sustained thereafter. %TBR1 did not change throughout the 4 time periods.

In the paediatric cohort, thirteen children also had at least 70% data uploaded in the two periods after lockdown (S1 Fig). There was no statistically significant difference across the four time periods in %TIR, %TAR1 and %TAR2, or %TBR1 (S3 Table). %TBR3 demonstrated significant variation (p = 0.03) with median percentages during the four observation periods of 0.08, 0.24, 0.18 and 0.05, respectively.

4.0 Discussion

These real-world data from a large specialist centre suggest that adults in an urban setting with T1D using glucose sensing technologies had an increase in time in range, with an associated reduction in time above range and reductions in measures of glucose variability during lockdown. Exposure to hypoglycaemia and hypoglycaemia risk assessed by LBGI did not change. Improvement in time in range was associated with being in the most deprived tertile, as was the reduction in time above range. This study adds to a growing body of evidence suggesting that lockdown is not associated with a deleterious effect on measures of glycaemia [7–10, 13–16, 24, 25].

The improved glycaemia in the adult cohort during this period of lockdown is likely to reflect the complex interplay of social, behavioural and environmental factors previously reported [7, 25, 26]. Even studies demonstrating a higher food intake [7] or specifically...
increased carbohydrate consumption without an increase in total daily insulin dose [16], more frequent snacking during lockdown [7], reduced physical activity [7, 25] and weight gain [25], did not find that lockdown had a detrimental effect on glycaemia. Perhaps the impact of these factors was outweighed by the imposed changes such as working from home, allowing for more frequent checking blood glucose values and meal eating habits, which are associated with better glycaemia control [27]. Meal eating habits are associated with daily routine [27], and people with diabetes have reported more regular mealtimes during lockdown [7]. Although individuals had altered access to usual diabetes care with reduced face-to-face contact during lockdown, remote support was provided by telephone or e-mail and this may have been more accessible for some people who find it challenging to attend clinics. A Spanish survey found that 97.9% agreed with the use of telemedicine, favouring telephone as their preferred means of communication [26].

Our study did not demonstrate an increase in scanning frequency in isCGM users. However, this only made up 64% of the adult cohort. In addition, despite greater scanning frequency, how individuals use that data is critical, and imposed restrictions on working from home may allow for improved lifestyle choices.

Other studies investigating the two week period following the end of lockdown, have found comparable results to our study, showing a sustained increase in %TIR and reduction in % TAR1 [14, 15] or TAR 251-400mg/dL [16]. A small Spanish dataset of participants on MDI using isCGM, found no change in glycaemic metrics between pre and during lockdown but an

| Table 4. Glycaemic outcomes in the pre-, during, immediately after and a month after lockdown (n = 97). | Adults (n = 97) |
|---------------------------------------------------------------|----------------|
| % time in range                                               |                |
| TIR: 3.9-10mmol/L (70 -180mg/dL)                              |                |
| Pre-lockdown                                                   | 56.7 (43.5–65.1) |
| During lockdown                                                | 60.2 (43.9–69.3) |
| Immediately after lockdown                                     | 59.5 (48.6–71.5) |
| 1 month after lockdown                                         | 59.1 (46.7–72.2) |
| p-value                                                       | <0.001*†‡      |
| % time in euglycaemia                                          |                |
| 3.9–7.8mmol/L (70 -140mg/dL)                                   |                |
| Pre-lockdown                                                   | 34.9 (24.5–39.9) |
| During lockdown                                                | 36.1 (24.9–45.7) |
| Immediately after lockdown                                     | 35.1 (26.1–44.3) |
| 1 month after lockdown                                         | 34.6 (25.4–47.4) |
| p-value                                                       | 0.010*†‡       |
| % time in hypoglycaemia                                        |                |
| TBR1: <3.9mmol/L (<70mg/dL)                                    |                |
| Pre-lockdown                                                   | 3.8 (1.5–6.6)   |
| During lockdown                                                | 3.8 (1.5–6.5)   |
| Immediately after lockdown                                     | 3.7 (1.4–7.0)   |
| 1 month after lockdown                                         | 3.4 (1.4–6.6)   |
| p-value                                                       | 0.59           |
| TBR2: <3.0mmol/L (<54 mg/L)                                    |                |
| Pre-lockdown                                                   | 0.8 (0.3–1.7)   |
| During lockdown                                                | 0.9 (0.2–2.0)   |
| Immediately after lockdown                                     | 0.8 (0.1–1.8)   |
| 1 month after lockdown                                         | 0.6 (0.2–1.9)   |
| p-value                                                       | 0.55           |
| TBR3: <2.8mmol/L (<50mg/L)                                    |                |
| Pre-lockdown                                                   | 0.5 (0.1–1.1)   |
| During lockdown                                                | 0.5 (0.1–1.3)   |
| Immediately after lockdown                                     | 0.5 (0.0–1.2)   |
| 1 month after lockdown                                         | 0.3 (0.1–1.3)   |
| p-value                                                       | 0.64           |
| % time in hyperglycaemia                                       |                |
| TAR1: >10mmol/L (>180mg/dL)                                    |                |
| Pre-lockdown                                                   | 38.0 (27.6–49.0) |
| During lockdown                                                | 33.8 (23.6–50.8) |
| Immediately after lockdown                                     | 34.9 (24.0–47.2) |
| 1 month after lockdown                                         | 36.4 (21.3–49.9) |
| p-value                                                       | <0.001*†‡      |
| TAR2: >13.9 mmol/L (>250mg/dL)                                 |                |
| Pre-lockdown                                                   | 11.3 (5.9–18.3) |
| During lockdown                                                | 8.4 (4.4–17.4)  |
| Immediately after lockdown                                     | 8.8 (3.3–17.0)  |
| 1 month after lockdown                                         | 8.8 (2.6–17.1)  |
| p-value                                                       | <0.001*†‡      |

**Glycaemic variability measures**

|                                | Pre-lockdown | During lockdown | Immediately after lockdown | 1 month after lockdown | p-value |
|--------------------------------|--------------|-----------------|----------------------------|------------------------|---------|
| Mean (8.4–10.2)                | 9.2 (8.4–10.2) | 9.0 (8.0–10.1)  | 9.1 (8.1–10.4)             | 9.1 (7.8–10.3)         | 0.004*†‡|
| GMI (%) (6.9–7.7)              | 7.3 (6.9–7.7)  | 7.2 (6.8–7.7)   | 7.2 (6.8–7.8)              | 7.2 (6.7–7.7)          | 0.004*†‡|
| GMI (mmol/mol)                 | 55.9 (52.0–60.8) | 54.9 (50.3–60.4) | 55.3 (50.8–61.6)          | 55.6 (49.5–61.0)       | <0.001*†‡|
| Standard deviation (3.0–4.1)   | 3.6 (3.0–4.1)  | 3.4 (2.8–3.8)   | 3.4 (2.8–3.9)             | 3.4 (2.8–3.8)          | 0.002*   |
| CV (%) (34.1–41.8)             | 38.8 (34.1–41.8) | 37.6 (33.5–40.8) | 37.3 (33.2–40.9)         | 36.5 (32.9–40.2)       | 0.75     |
| LBGI (0.5–1.6)                 | 0.9 (0.5–1.6)  | 1.0 (0.5–1.6)   | 0.9 (0.4–1.9)             | 0.9 (0.4–1.7)          | <0.001*†‡|
| MAG (2.2–3.0)                  | 2.5 (2.2–3.0)  | 2.4 (2.1–2.8)   | 2.0 (1.0–2.3)             | 1.9 (1.0–2.3)          | <0.001*†‡|

Results expressed as median (IQR). P-value calculated by Friedman test comparing glycaemic variables between the four time periods. For between group sub-analysis *pre-lockdown vs during lockdown p<0.05analysis †pre-lockdown vs immediately after lockdown p<0.05analysis ‡ pre-lockdown vs 1 month after lockdown p<0.05. Abbreviations: CV, coefficient of variation; GMI, glucose management indicator; LBGI, low blood glucose index; MAG, mean absolute glucose; TAR, time above range; TBR, time below range; TIR, time in range.

https://doi.org/10.1371/journal.pone.0254951.1004
improvement in %TIR (p = 0.05) and %TAR1 and %TAR2 post lockdown compared to before [28].

The numbers in the paediatric cohort were small and changes did not reach statistical significance, but effect sizes were similar to those seen adults. Our results are comparable to other studies in children and adolescents which reported no significant increase in %TIR during lockdown [11, 29, 30]. Conversely, other studies have demonstrated an increase in %TIR for participants [12], including those using hybrid closed loop systems [10, 13]. Reports in children have shown reduced time for physical activities [12], an increase in screen time [31], an increase in consumption of sweet and fried food in adolescents [32] and a change to meal patterns [30], emphasising the complex social factors involved. Nevertheless, many of the factors contributing to improved glycaemia in adults are likely to be shared in children. In addition, increased parental supervision during lockdown may have influenced behaviour, including the frequency and timing of insulin delivery in relation to food, particularly considering that 25 percent of adolescents report missed insulin injections [33]. The significant reduction in MAG in paediatrics during lockdown suggests decreased glucose variation which may in part reflect better insulin matching to food, given inaccurate carbohydrate counting has been associated with higher glycaemic variability in adults [34].

A small Italian dataset in adolescents during partial relaxation of restrictions and at the end of lockdown, found a sustained improvement in %TIR and a reduction in %TBR from lockdown onwards compared to pre lockdown [17]. However, all these participants used hybrid closed loop system with an increase in percentage time in auto mode at the end of lockdown compared to pre lockdown [17].

Multivariable analysis in adults and paediatrics indicated people in the lower 50% of the deprivation scores improved %TIR more than those in the upper 50%. The cause for this novel finding is unclear, but, with lower dietary quality scores in the most disadvantaged [35], may reflect reduced access to less healthy lifestyle choices, increased time and capacity for self-management tasks, or increased engagement with education and support as remote consultations may be less burdensome and more accessible than clinic visits. Furthermore, lower socioeconomic status is associated with higher HbA1c as seen in the T1D Exchange registry, which may enable greater room for changes in glycaemia towards improvement [36]. Our results differ from the findings in Scotland, which suggested higher levels of socioeconomic deprivation were an independent predictor of deteriorating glycaemic control [8].

In our regression model, rtCGM use was likely to be associated with increased %TBR1 hypoglycaemia during lockdown despite no overall increase in time below range being observed in between-group comparisons. This association was not observed for %TBR2. In the UK, rtCGM is reimbursed by the National Health Service (NHS) for people with T1D at highest risk of hypoglycaemia, including those experiencing severe hypoglycaemia, loss of awareness of hypoglycaemia, hypoglycaemia that is causing problems with daily activities, and extreme fear of hypoglycaemia [37]. Behaviours associated with exposure to hypoglycaemia [38] may be enabled during lockdown, increasing exposure to mild hypoglycaemia, but the absence of an association with clinically important hypoglycaemia is reassuring. A reduction was seen in hypoglycaemia in people using isCGM but not rtCGM. This may reflect the lower TBR in the rtCGM group at baseline as the addition of alerts and alarms, even in a higher risk group, kept hypoglycaemia to a minimum and further improvement was not detectable.

The strengths of this study include inclusion of adults and children, inclusion of people at highest risk of hypoglycaemia and a large, diverse population of people using CSII and MDI regimens. We analysed study periods of 28 days, increasing the robustness of the CGM derived metrics, with a longer time period analysed than other studies pre and during lockdown [7–9, 39, 40] and also after lockdown [14–17, 28]. Although >70% of 14 days rtCGM data is the
minimum recommended period for most evaluated metrics [21], metrics related to hypoglycaemia in particular require longer duration due to higher error and variance [41]. Very importantly, we include deprivation in our analysis.

Limitations to our analyses include missing insulin, dietary intake, education, occupation, and physical activity data. Also, further analyses additionally including people using capillary blood glucose testing would have value. In identifying likely prominent features of glycaemia during lockdown, we carried out a number of statistical tests and it is possible that some significances may have arisen by chance. Nevertheless, our principal outcome variables: \( \% \text{TIR} \) and CV were both significant at \( p < 0.01 \), and statistical testing was generally used as a guide to interpretation in our analysis. Our findings could be regarded as hypothesis-generating, but it should be emphasised that lockdown constituted an unprecedented change in lifestyle.

In conclusion, glycaemia in adults improved during lockdown, particularly in people from more deprived areas, and was sustained post relaxation of lockdown. The improved glycaemia is likely to be a result of complex social, behavioural, and environmental factors influencing lifestyle during COVID-19. A similar effect size for glycaemic outcomes was observed in children, but the smaller sample size limited definitive conclusions. There was no deterioration in glycaemia associated with lifestyle during the EOHO Government scheme in the UK. Future studies including a larger number of children are recommended, as are detailed analyses of the differential behaviour changes seen across deprivation categories.

**Supporting information**

**S1 Table.** Pairwise analysis of glycaemic outcomes for CSII and MDI users in adults. Participants used rtCGM/ isCGM for at least 70% of time with at least 70% data uploaded for both time periods (as per consensus recommendations). All data presented as median (IQR). Abbreviations: CSII, continuous subcutaneous insulin infusion; CV, coefficient of variation; GMI, glucose management indicator; LBGI, low blood glucose index; MAG, mean absolute glucose; MDI, multiple daily injections of insulin; TAR, time above range; TBR, time below range; TIR, time in range.

(DOCX)

**S2 Table.** Pairwise analysis of glycaemic outcomes for rtCGM and isCGM users in adults. Participants used rtCGM/ isCGM for at least 70% of time with at least 70% data uploaded for both time periods (as per consensus recommendations). All data presented as median (IQR). Abbreviations: CV, coefficient of variation; GMI, glucose management indicator; isCGM, intermittently scanning continuous glucose monitoring; LBGI, low blood glucose index; MAG, mean absolute glucose; rtCGM, real-time continuous glucose monitoring; TAR, time above range; TBR, time below range; TIR, time in range.

(DOCX)

**S3 Table.** Paediatric analysis of glycaemic outcomes pre-, during, immediately after and a month after lockdown (n = 13). Participants used rtCGM/ isCGM for at least 70% of time with at least 70% data uploaded for all four time periods (as per consensus recommendations). P-value calculated by Friedman test comparing glycaemic variables between the four time periods. All data presented as median (IQR). Abbreviations: CV, coefficient of variation; GMI, glucose management indicator; LBGI, low blood glucose index; MAG, mean absolute glucose; TAR, time above range; TBR, time below range; TIR, time in range.

(DOCX)
S1 Fig. Recruitment flowchart. Abbreviations: FSL, flash glucose monitoring; rtCGM, real-time continuous glucose monitoring.

S2 Fig. Box plot to demonstrate the change in %TIR by tertiles for adults and children included in the pair-wise analysis (n = 145) using the English index of multiple deprivation 2019. The “most deprived” tertile include deciles 1–3 (n = 52), the “moderately deprived” tertile includes deciles 4–5 (n = 43) and the “least deprived” tertiles includes deciles 6–10 (n = 50). Abbreviations: TIR, time in range.

Acknowledgments
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Author Contributions
Conceptualization: Nick Oliver.
Data curation: Parizad Avari, Rebecca Unsworth, Siân Rilstone, Chukwuma Uduku.
Formal analysis: Parizad Avari, Rebecca Unsworth.
Investigation: Parizad Avari.
Methodology: Parizad Avari, Rebecca Unsworth, Siân Rilstone, Chukwuma Uduku, Ian F. Godsland, Nick Oliver.
Supervision: Karen M. Logan, Neil E. Hill, Ian F. Godsland, Monika Reddy, Nick Oliver.
Writing – original draft: Parizad Avari, Rebecca Unsworth.
Writing – review & editing: Parizad Avari, Rebecca Unsworth, Siân Rilstone, Chukwuma Uduku, Karen M. Logan, Neil E. Hill, Ian F. Godsland, Monika Reddy, Nick Oliver.

References
1. WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020 [Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020/]
2. P.M.Address to the nation on Coronavirus: 23 March 2020 [Available from: https://www.gov.uk/government/speeches/pm-address-to-the-nation-on-coronavirus-23-march-2020.]
3. Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020; 8(10):813–22. https://doi.org/10.1016/S2213-8587(20)30272-2 PMID: 32798472
4. Holman N, Knighton P, Kar P, O’Keefe J, Curley M, Weaver A, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020; 8(10):823–33. https://doi.org/10.1016/S2213-8587(20)30271-0 PMID: 32798471
5. Maddaloni E, Buzzetti R. Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes/Metabolism Research Reviews. 2020:e3213321. https://doi.org/10.1002/dmrr.3321 PMID: 32233018
6. Reddy M, Rilstone S, Cooper P, Oliver NS. Type 1 diabetes in adults: supporting self management. Bmj. 2016;352. https://doi.org/10.1136/bmj.i996 PMID: 26905473
7. Capaldo B, Annuzzi G, Creanza A, Giglio C, De Angelis R, Lupoli R, et al. Blood Glucose Control During Lockdown for COVID-19: CGM Metrics in Italian Adults With Type 1 Diabetes. Diabetes Care. 2020; 43 (8):e88–e9. https://doi.org/10.2337/dc20-1127 PMID: 32540921
8. Dover AR, Ritchie SA, McKnight JA, Strachan MWJ, Zammitt NN, Wake D, et al. Assessment of the effect of the COVID-19 lockdown on glycemic control in people with type 1 diabetes using flash glucose monitoring. Diabetic Medicine. 2021; 38(1):e14374. https://doi.org/10.1111/dme.14374 PMID: 32740984

9. Mesa A, Viñals C, Pueyo I, Roca D, Vidal M, Giménez M, et al. The impact of strict COVID-19 lockdown in Spain on glycemetic profiles in patients with type 1 Diabetes prone to hypoglycemia using standalone continuous glucose monitoring. Diabetes research and clinical practice. 2020; 167:108354. https://doi.org/10.1016/j.diabres.2020.108354 PMID: 32739380

10. Schiaffini R, Barbetti F, Rapini N, Inzaghi E, Deodati A, Patara IP, et al. School and pre-school children with type 1 diabetes during Covid-19 quarantine: The synergic effect of parental care and technology. Diabetes research and clinical practice. 2020; 166:108302. https://doi.org/10.1016/j.diabres.2020.108302 PMID: 32623034

11. Di Dalmazi G, Maltoni G, Bongiorno C, Tucci L, Di Natale V, Moscatello S, et al. Comparison of the effects of lockdown due to COVID-19 on glucose patterns among children, adolescents, and adults with type 1 diabetes: CGM study. BMJ open diabetes res. 2020; 8(2).

12. Predieri B, Leo F, Candia F, Lucaccioli L, Madeo SF, Pugliese M, et al. Glycemic Control Improvement in Italian Children and Adolescents With Type 1 Diabetes Followed Through Telemedicine During Lockdown Due to the COVID-19 Pandemic. Frontiers in endocrinology. 2020; 11:965. https://doi.org/10.3389/fendo.2020.595735 PMID: 33424771

13. Tomese G, Ceconi V, Monasta L, Carletti C, Faleschini E, Barbi E. Glycemic control in type 1 diabetes mellitus during COVID-19 pandemic and the role of in-home physical activity. Diabetes Technol Ther. 2020; 22(6):462–7. https://doi.org/10.1089/dia.2020.0169 PMID: 32421355

14. Aragona M, Rodia C, Bertolotto A, Campi F, Coppelli A, Giannarelli R, et al. Type 1 diabetes and COVID-19: The "lockdown effect." Diabetes research and clinical practice. 2020; 170:108468. https://doi.org/10.1016/j.diabres.2020.108468 PMID: 32987040

15. Moreno-Dominguez O, Gonzalez-Perez de Villar N, Barquiel B, Hillman-Gadea N, Gaspar-Lafuente R, Arevalo-Gomez M, et al. Factors Related to Improvement of Glycemic Control Among Adults with Type 1 Diabetes During Lockdown Due to COVID-19. Diabetes technology & therapeutics. 2020: https://doi.org/10.1089/dia.2020.0550 PMID: 33237817

16. Longo M, Caruso P, Petrizzo M, Castaldo F, Sarnato A, Giachino M, et al. Glycemic control in people with type 1 diabetes using a hybrid closed loop system and followed by telemicine during the COVID-19 pandemic in Italy. Diabetes research and clinical practice. 2020; 169:108440. https://doi.org/10.1016/j.diabres.2020.108440 PMID: 32926958

17. Ceconi V, Barbi E, Tomese G. Glycemic control in type 1 diabetes mellitus and COVID-19 lockdown: What comes after a “quarantine”? Journal of diabetes. 2020: https://doi.org/10.1111/1753-0407.13110 PMID: 32909344

18. Official Statistics. Eat out to Help Out statistics commentary. Published 25 November 2020. [Available from: https://www.gov.uk/government/publications/eat-out-to-help-out-statistics-eat-out-to-help-out-statistics-commentary.

19. Ministry of Housing, Communities and Local Government. The English Indices of Deprivation 2019 [Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/853811/IoD2019_FAQ_v4.pdf.

20. Avari P, Ramli R, Reddy M, Oliver N, Fothergill R. Rationale and protocol for the Assessment of Impact of Real-time Continuous Glucose Monitoring on people presenting with severe Hypoglycaemia (AIR-CGM) study. BMC Endocrine Disorders. 2019; 19(1):1–7. https://doi.org/10.1186/s12902-018-0327-2 PMID: 30606164

21. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019; 42(8):659–603. https://doi.org/10.2337/dc19-0028 PMID: 31177185

22. Moscardo V, Gimenez M, Oliver N, Hill NR. Updated Software for Automated Assessment of Glucose Variability and Quality of Glycemic Control in Diabetes. Diabetes Technology & Therapeutics. 2020; 22 (10):701–8. https://doi.org/10.1089/dia.2019.0416 PMID: 32195607

23. Research JCH. Glycemic Management Indicator (GMI) [Available from: https://www.jaeb.org/gmi.

24. Bonora BM, Boscari F, Avogaro A, Bruttomesso D, Fadini GP. Glycaemic Control Among People with Type 1 Diabetes During Lockdown for the SARS-CoV-2 Outbreak in Italy. Diabetes Ther. 2020:1–11. https://doi.org/10.1007/s13300-020-00829-7 PMID: 32395187

25. Ruissen MM, Regehr H, Landstra CP, Schroeijen M, Jazet I, NIHoff MF, et al. Increased stress, weight gain and less exercise in relation to glycemic control in people with type 1 and type 2 diabetes during the COVID-19 pandemic. BMJ open diabetes res. 2021; 9(1).
26. Tejera-Perez C, Moreno-Perez O, Rios J, Reyes-Garcia R. People living with type 1 diabetes point of view in COVID-19 times (COVIDT1 study): Disease impact, health system pitfalls and lessons for the future. Diabetes research and clinical practice. 2020; 171:108547. https://doi.org/10.1016/j.diabres.2020.108547 PMID: 33278422

27. Hanna KM, Kupczyk KA, Hansen JR, Jones-Ryan ML, Drincic AT. Association of habits, triggers, glycemic control, routines, stress and impulse control among emerging adults with type 1 diabetes. Diabetic medicine: a journal of the British Diabetic Association. 2020:e14370. https://doi.org/10.1111/dme.14370 PMID: 33278422

28. Cotovad-Bellas L, Tejera-Perez C, Prieto-Tenreiro A, Sanchez-Bao A, Bellido-Guerrero D. The challenge of diabetes home control in COVID-19 times: Proof is in the pudding. Diabetes research and clinical practice. 2020; 168:108379. https://doi.org/10.1016/j.diabres.2020.108379 PMID: 32853692

29. Brener A, Mazor-Aronovitch K, Rachmil M, Levek N, Barash G, Pinhas-Hamiel O, et al. Lessons learned from the continuous glucose monitoring metrics in pediatric patients with type 1 diabetes under COVID-19 lockdown. Acta diabetologica. 2020; 57(12):1511–7. https://doi.org/10.1007/s00592-020-01596-4 PMID: 33026497

30. Christoforidis A, Kavoura E, Nemtsa A, Pappa K, Dimitriadou M. Coronavirus lockdown effect on type 1 diabetes management in children wearing insulin pump equipped with continuous glucose monitoring system. Diabetes research and clinical practice. 2020; 166:108307. https://doi.org/10.1016/j.diabres.2020.108307 PMID: 32650036

31. Pietrobelli A, Pecoraro L, Ferruzzi A, Heo M, Faith M, Zoller T, et al. Effects of COVID-19 Lockdown on Lifestyle Behaviors in Children with Obesity Living in Verona, Italy: A Longitudinal Study. Obesity (Silver Spring). 2020; 28(8):1382–8. https://doi.org/10.1002/oby.22861 PMID: 32352652

32. Ruiz-Roso MB, de Carvalho Padilha P, Mantilla-Escalante DC, Ulloa N, Brun P, Acevedo-Corra D, et al. COVID-19 Confinement and Changes of Adolescent’s Dietary Trends in Italy, Spain, Chile, Colombia and Brazil. Nutrients. 2020; 12(6):1807.

33. Weissberg-Benchell J, Glasgow AM, Typan WD, Wirtz P, Turek J, Ward J. Adolescent Diabetes Management and Mismanagement. Diabetes Care. 1995; 18(1):77–82. https://doi.org/10.2337/diacare.18.1.77 PMID: 7698052

34. Brazeau A, Micrescu H, Desjardins K, Leroux C, Stryciar I, Ekoé J, et al. Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes. Diabetes research and clinical practice. 2013; 99(1):19–23. https://doi.org/10.1016/j.diabres.2012.10.024 PMID: 23146371

35. Backholer K, Spencer E, Gearon E, Magliano DJ, McNaughton SA, Shaw JE, et al. The association between socio-economic position and diet quality in Australian adults. Public Health Nutrition. 2016; 19(3):477–85. https://doi.org/10.1017/S1368980015001470 PMID: 25989940

36. Miller KM, Beck RW, Foster NC, Maahs DM. HbA1c Levels in Type 1 Diabetes from Early Childhood to Older Adults: A Deeper Dive into the Influence of Technology and Socioeconomic Status on HbA1c in the T1D Exchange Clinic Registry Findings. Diabetes Technology & Therapeutics. 2020; 22(9):645–50. https://doi.org/10.1089/dia.2019.0393 PMID: 31905008

37. Type 1 diabetes in adults: diagnosis and management. NICE guideline [NG17]. [Available from: https://www.nice.org.uk/guidance/ng17]

38. Rogers HA, De Zoyza N, Amiel SA. Patient experience of hypoglycaemia unawareness in Type 1 diabetes: are patients appropriately concerned? Diabetic Medicine. 2012; 29(3):321–7. https://doi.org/10.1111/j.1464-5491.2011.03444.x PMID: 21913969

39. Maddaloni E, Coraggio L, Plerisic S, Carlone A, Pozzilli P, Buzzetti R. Effects of COVID-19 Lockdown on Glucose Control: Continuous Glucose Monitoring Data From People With Diabetes on Intensive Insulin Therapy. Diabetes Care. 2020; 43(8):e86–e7. https://doi.org/10.2337/dc20-0954 PMID: 32503838

40. Fernández E, Cortazar A, Bellido V. Impact of COVID-19 lockdown on glycemic control in patients with type 1 diabetes. Diabetes research and clinical practice. 2020; 166:108348. https://doi.org/10.1016/j.diabres.2020.108348 PMID: 32710100

41. Herrero P, Alaiti A, Reddy M, Georgiou P, Oliver N. Robust determination of the optimal continuous glucose monitoring length of intervention to evaluate long-term glycemic control (Abstract). The Official Journal of ATTD Advanced Technologies & Treatments for Diabetes Conference Madrid, Spain—February 19–22, 2020 in Diabetes Technology & Therapeutics Diabetes Technology & Therapeutics [Internet]. 2020 30th June 2020; 22:[A-1-A-250 pp.].